Treatment of chronic hepatitis B;Traitement de l'hépatite chronique B

Presse Medicale

Volumn 35, Issue 2 II, 2006, Pages 327-334

  Asselah, Tarik ^a   Castelnau, Corinne ^a   Marcellin, Patrick ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; INTERFERON; LAMIVUDINE; PEGINTERFERON;

ARTHRALGIA; ASTHENIA; CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; DRUG TOLERABILITY; FEVER; FIBROSIS; HEADACHE; HEPATITIS B; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNOLOGICAL TOLERANCE; INJECTION SITE REACTION; NEUTROPENIA; REMISSION; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SKIN INFLAMMATION; VIRUS REPLICATION;

EID: 33344470942     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(06)74578-X     Document Type: Article

References (40)

1. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol. 2003; 39 S1: S3-25.
2. Lok AS, McMahon BJ. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Chronic hepatitis B. Hepatology. 2001; 34: 1225-41.
3. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med. 2004; 350: 1118-29.
4. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology. 2000; 32: 477-81.
5. Nousbaum JB, Cadranel JF, Bonnemaison G, Bourliere M, Chiche L, Chor H et al. Clinical practice guidelines on the use of liver biopsy. Gastroenterol Clin Biol. 2002; 26: 848.
6. Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology. 2002; 36: 1425-30.
7. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005; 365: 123-9.
8. Westland C, Delaney W 4th, Yang H, Chen SS, Marcellin P, Hadziyannis S et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology. 2003; 125: 107-16.
9. Thomas H, Foster G, Platis D. Mechanisms of action of interferon and nucleoside analogues. J Hepatol. 2003; 39 Suppl 1: S93-S98.
10. Asselah T, Boyer N, Marcellin P. Traitement de l'hépatite C. Encycl Méd Chir. Hépatologie. 2003, 7-015-B-51.
11. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993; 119: 312-23.
12. Craxi A, Di Bona D, Camma C. Interferon-alpha for HBeAg-positive chronic hepatitis B. J Hepatol. 2003; 39 S1: S99-105.
13. Brunetto MR, Oliveri F, Colombatto P, Coco B, Ciccorossi P, Bonino F. Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon. J Hepatol. 2003; 39 S1: S164-7.
14. Gervais A, Boyer N, Marcellin P. Tolerability of treatments for viral hepatitis. Drug Saf. 2001; 24: 375-84.
15. Marcellin P, Pouteau M, Benhamou JP. Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. J Hepatol. 1995; 22: 364-9.
16. Boyer N, Marcellin P. L'interféron pegylé: nouveau progrès dans le traitement de l'hépatite chronique virale C. Gastroenterol Clin Biol. 2000; 24: 767-9.
17. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 2003; 10: 298-305.
18. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005; 352: 2682-95.
19. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004; 351: 1206-17.
20. Dienstag JL, Schiff E, Wright T, Perrillo R. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999; 341: 1256-63
21. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology. 2000; 31: 207-10.
22. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY et al. On behalf of the Asia Hepatitis Lamivudine Study Group. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology. 2001; 33: 1527-32.
23. Jonas MM, Kelley DA, Mizerski J, Badia IB, Areias JA, Schwarz KB et al. International Pediatric Lamivudine Investigator Group. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med. 2002; 346: 1706-13.
24. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003; 124: 105-17.
25. Zoulim F. Hepatitis B virus resistance to antivirals: clinical implications and management. J Hepatol. 2003; 39 Suppl 1: S133-8.
26. Honkoop P, de Man RA, Niesters HGM, Zondervan PE, Schalm SW. Severe acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology. 2000; 32: 635-9.
27. Liaw YF et al. Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blind placebo controlled clinical trial. Hepatology. 2003; 38: 220A.
28. Tassopoulos N, Hadziyannis S, Cianciara J, Rizzetto M, Schiff E, Pastore G et al. Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy. Hepatology. 2001; 34 S: 341A.
29. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML et al. Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003; 348: 808-16.
30. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M et al. Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003; 348: 800-7.
31. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005; 352: 2673-81.
32. Perrillo RP, Schiff ER, Yoshida E, Statler A, Hirsch K, Wright T et al. Adefovir Dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129-34.
33. Schiff ER, Lai CE, Hadziyannis S, Neuhaus P, Terrault N, Colombo M et al. Behalf of the Adefovir Dipovoxil Study 435 International Investigators Group. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology. 2003; 38:1419-27.
34. Peters MG, Hann Hw H, Martin P, Heathcote EJ, Buggisch P, Rubin R et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2004; 126: 91-101.
35. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2004; 126: 81-90.
36. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet. 2001; 358: 718-23.
37. Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology. 2005; 129 (4): 1198-209.
38. De Man RA, Wolters LMM, Nevens F, Chua D, Sherman M, Lai CE et al. Safety and Efficay of oral Entecavir given for 28 days in patients with chronic hepatitis B. Hepatology. 2001; 34: 578-82.
39. Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N, Dehertogh D. Entecavir is superior to lamivudine in reducing HBV DNA inpatients with chronic hepatitis B infection. Gastroenterology. 2002; 123: 1831-8.
40. Tassopoulos N, Hadziyannis S, Cianciara J, Rizzetto M, Schiff E, Pastore G et al. Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy. Hepatology. 2001; 34: 340A.